



QIAstat-Dx[®]. Fast. Reliable. Accurate.

Improve care for community-acquired meningitis with QIAstat-Dx



Bacterial meningitis requires swift, precise diagnosis

Bacterial meningitis can become fatal within just 24–48 hours, even in otherwise healthy individuals. With cases on the rise in the U.S. (1), early recognition and rapid diagnosis have never been more important (2).

Traditional methods aren't enough



Delayed diagnosis

Traditional methods can take up to three days, delaying critical treatment decisions (3).



Low diagnostic yield

Antibiotic pretreatment reduces the efficacy of cerebrospinal fluid (CSF) culture results (3).



Inappropriate empiric treatment

Many patients undergo unnecessary treatment, resulting in inappropriate or prolonged therapy (3).



High healthcare costs

Extended hospital stays and unnecessary treatments strain healthcare resources (4).

Complement your current algorithm with the QIAstat-Dx ME Panel



Easy workflow

Minimizes contamination risk, with no reagent preparation needed and just one sample handling step.



Rapid turnaround

Reliable results within hours, supporting faster clinical decisions.



Enhanced diagnostic yield

RT-PCR provides accurate results even after intravenous antibiotic treatment (3).




Broad bacterial detection

The only syndromic test that covers all reportable invasive bacterial diseases detectable in CSF (5).

QIAstat-Dx ME Panel provides accurate answers fast

Our QIAstat-Dx syndromic tests are simple and user-friendly. A quick and easy workflow can help you get crucial results fast, supporting timely patient care.



Bacteria

Escherichia coli K1
Haemophilus influenzae
Listeria monocytogenes
Neisseria meningitidis (encapsulated)
Streptococcus agalactiae
Streptococcus pneumoniae
Streptococcus pyogenes

Virus

Enterovirus

Fungi

*Cryptococcus neoformans/gattii**

Blue: Target unique to the QIAstat-Dx ME Panel.

Quick enterovirus detection may improve outcomes for patients and hospitals

Enterovirus (EV) is the most common cause of meningitis and encephalitis. Yet, patients with EV typically receive empiric antibiotics and remain hospitalized for an average of three days while awaiting test results (6).

The QIAstat-Dx ME Panel may help reduce delays in providing appropriate care for your patients.

Our test delivers same-day results, enabling the simultaneous detection of EV and exclusion of bacterial causes. This has the potential to (4):



Reduce unnecessary antibiotic use



Significantly shorten hospital stays

Tailored patient care starts here: QIAstat-Dx panel menu

Optimize your diagnostic approach and provide better individual care with our targeted and extended panels.

Panel	Cat. no.
 QIAstat-Dx ME Panel	691621
 QIAstat-Dx Respiratory Panel Plus	691224
 QIAstat-Dx Respiratory Panel Mini	691218
 QIAstat-Dx Gastrointestinal Panel 2	691421
 QIAstat-Dx Gastrointestinal Panel 2 Mini B + V	691424
 QIAstat-Dx Gastrointestinal Panel 2 Mini B	This product is under development.

References:

- Centers for Disease Control and Prevention. Increase in invasive serogroup Y meningococcal disease in the United States. CDC Health Alert Network. Published March 28, 2024. Accessed January 6, 2025. <https://www.cdc.gov/han/2024/han00505.html>.
- Centers for Disease Control and Prevention. ABCs Bact Facts Interactive Data Dashboard. Updated May 22, 2024. Accessed January 6, 2025. <https://www.cdc.gov/abcs/bact-facts/data-dashboard.html>.
- Miller JM, et al. *Clin Infect Dis*. 2024 Mar 5;ciae104. doi: 10.1093/cid/ciae104.
- Nigrovic LE, Chiang VW. *Arch Pediatr Adolesc Med*. 2000;154(8):817–821. doi:10.1001/archpedi.154.8.8175.
- Centers for Disease Control and Prevention. Active Bacterial Core surveillance. Updated May 15, 2024. Accessed January 6, 2025. <https://www.cdc.gov/abcs/about/index.html>.
- Hasbun R, et al. *Clin Infect Dis*. 2017;65(3):359–363. doi:10.1093/cid/cix319.

* *Cryptococcus neoformans*/*Cryptococcus gattii* are both detected, but not differentiated, with the QIAstat-Dx ME Panel.

For up-to-date licensing information and product-specific disclaimers, see the respective QIAGEN kit instructions for use or user manual. QIAGEN instructions for use and user manuals are available at www.qiagen.com or can be requested from QIAGEN Technical Services (or your local distributor).



Explore clinical cases, epidemiology updates, publication summaries and more at qiagen.com/qiastat-dx

Trademarks: QIAGEN®, Sample to Insight®, QIASphere®, QIAstat-Dx® (QIAGEN Group). Registered names, trademarks, etc. used in this document, even when not specifically marked as such, are not to be considered unprotected by law. PROM-23555-001 QPRO-9403 01/2025 © 2025 QIAGEN, all rights reserved.

Ordering
Technical Support
Website

www.qiagen.com/shop
www.support.qiagen.com
www.qiagen.com